Phosducin-like protein levels in leukocytes of patients with major depression and in rat cortex: the effect of chronic treatment with antidepressants

Psychiatry Research
Angela Matuzany-RubanSofia Avissar

Abstract

The importance of signal transduction processes beyond receptors involving receptor-G protein coupling, in both the pathophysiology and the treatment of mood disorders, is well documented. Thus, regulatory elements of G protein function may play a role in the molecular mechanisms underlying these alterations. Phosducin-like proteins, a family of regulators of G protein function expressed throughout brain and body, modulate G protein function by high affinity sequestration of G protein-betagamma subunits, thus impeding G protein-mediated signal transmission by both Galpha and Gbetagamma subunits. An important consequence of Gbetagamma neutralization is the prevention of G protein-coupled receptor kinase phosphorylation resulting in a temporary protection to agonist-bound receptor desensitization. Phosducin-like protein levels were measured in brain cortices of rats chronically treated with one of five classes of antidepressants: imipramine, venlafaxine, maprotiline, citalopram, and moclobemide. None of the antidepressant treatments had any significant effect on phosducin-like protein levels. Phosducin-like protein levels were evaluated in mononuclear leukocytes from a group of 15 patients diagnosed with major depressive episode,...Continue Reading

References

Nov 1, 1965·The American Journal of Psychiatry·J J Schildkraut
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·W H BerrettiniE S Gershon
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M F MilesM Elliott
May 17, 1996·The Journal of Biological Chemistry·S MüllerM J Lohse
May 9, 1997·The Journal of Biological Chemistry·C ThibaultM F Miles
Jan 1, 1997·Genetic Epidemiology·J Rice
May 30, 1998·Naunyn-Schmiedeberg's Archives of Pharmacology·P H Bauer, M J Lohse
Dec 23, 1998·Psychiatric Genetics·W H BerrettiniL Ala-Kokko
Jul 14, 1999·American Journal of Medical Genetics·T SaitoH M Lachman
Feb 24, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·R Schulz
May 22, 2001·Archives of Biochemistry and Biophysics·N MinadeoD M de Freitas
Feb 23, 2002·Trends in Cell Biology·Stephen J Perry, Robert J Lefkowitz
May 17, 2002·Neuropharmacology·J GarzónP Sánchez-Blázquez
May 25, 2002·Human Molecular Genetics·Kodavali V ChowdariVishwajit L Nimgaonkar
Jun 18, 2002·Trends in Molecular Medicine·Sofia Avissar, Gabriel Schreiber
Dec 6, 2002·The Journal of Biological Chemistry·Jan HumrichMartin J Lohse
Jan 17, 2003·Expert Review of Molecular Diagnostics·Gabriel Schreiber, Sofia Avissar
Mar 26, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alessandro SerrettiEnrico Smeraldi
Sep 27, 2003·Biological Psychiatry·Matthäus WilleitBrigitta Bondy
Nov 25, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jesús A García-SevillaEnric Alvarez
Oct 30, 2004·The American Journal of Psychiatry·Sofia AvissarGabriel Schreiber

❮ Previous
Next ❯

Citations

Dec 26, 2006·Expert Review of Neurotherapeutics·Gabriel Schreiber, Sofia Avissar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.